See more : Enstar Group Limited (ESGRO) Income Statement Analysis – Financial Results
Complete financial analysis of MERCK Kommanditgesellschaft auf Aktien (MKGAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MERCK Kommanditgesellschaft auf Aktien, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Kajima Corporation (KAJMY) Income Statement Analysis – Financial Results
- China Greenland Broad Greenstate Group Company Limited (1253.HK) Income Statement Analysis – Financial Results
- SICC Co., Ltd. (688234.SS) Income Statement Analysis – Financial Results
- Scholastic Corporation (SCHL) Income Statement Analysis – Financial Results
- PT Argha Karya Prima Industry Tbk (AKPI.JK) Income Statement Analysis – Financial Results
MERCK Kommanditgesellschaft auf Aktien (MKGAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.merckgroup.com
About MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and electronics sectors worldwide. It discovers, develops, manufactures, and markets pharmaceutical and biological prescription drugs to treat neurology and immunology, oncology, fertility, and cardiology metabolism and endocrinology. The company also supplies products, tools, and services for research laboratories, pharma and biotech production, and industrial and testing laboratories. In addition, it offers material for integrated circuits, liquid crystals, organic light-emitting diodes, photoresists, smart antenna, and liquid crystal glazing solutions, as well as effect pigments for use in automotive coatings, cosmetics, industrial, and plastic applications. It has strategic alliances with Pfizer Inc.; agreement with Novartis AG; and license agreements with Debiopharm International SA and MoonLake Immunotherapeutics AG. The company was founded in 1668 and is headquartered in Darmstadt, Germany. MERCK Kommanditgesellschaft auf Aktien is a subsidiary of E. Merck Kommanditgesellschaft.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.99B | 22.23B | 19.69B | 17.53B | 16.15B | 14.84B | 15.33B | 15.02B | 12.84B | 11.50B | 11.10B | 11.17B | 10.28B | 9.29B | 7.75B | 7.56B | 7.06B | 6.26B | 5.87B | 5.34B | 7.20B | 7.40B |
| Cost of Revenue | 8.56B | 8.53B | 7.35B | 6.84B | 6.01B | 5.38B | 5.32B | 5.20B | 4.08B | 4.06B | 3.56B | 3.74B | 2.79B | 2.39B | 2.03B | 1.91B | 1.78B | 2.41B | 2.37B | 2.25B | 3.57B | 3.79B |
| Gross Profit | 12.44B | 13.71B | 12.34B | 10.70B | 10.15B | 9.45B | 10.01B | 9.82B | 8.77B | 7.44B | 7.54B | 7.44B | 7.49B | 6.91B | 5.72B | 5.65B | 5.28B | 3.84B | 3.50B | 3.09B | 3.63B | 3.61B |
| Gross Profit Ratio | 59.23% | 61.65% | 62.66% | 61.02% | 62.82% | 63.72% | 65.29% | 65.38% | 68.26% | 64.66% | 67.92% | 66.55% | 72.87% | 74.32% | 73.81% | 74.78% | 74.78% | 61.43% | 59.64% | 57.87% | 50.40% | 48.72% |
| Research & Development | 2.45B | 2.52B | 2.41B | 2.29B | 2.27B | 2.23B | 2.14B | 1.98B | 1.71B | 1.70B | 1.50B | 1.51B | 1.52B | 1.40B | 1.34B | 1.23B | 1.03B | 751.60M | 713.00M | 599.00M | 604.60M | 608.20M |
| General & Administrative | 1.39B | 1.31B | 1.24B | 1.19B | 1.15B | 993.00M | 930.00M | 854.00M | 719.90M | 608.60M | 562.40M | 552.20M | 1.01B | 478.20M | 424.90M | 446.20M | 444.70M | 386.70M | 354.70M | 329.20M | 412.40M | 468.00M |
| Selling & Marketing | 3.91B | 4.10B | 3.71B | 3.57B | 3.65B | 3.41B | 3.69B | 3.50B | 3.27B | 2.39B | 2.33B | 2.41B | 2.39B | 2.23B | 2.27B | 2.10B | 1.93B | 1.48B | 1.47B | 1.34B | 1.72B | 1.77B |
| SG&A | 5.31B | 5.40B | 4.96B | 4.76B | 4.81B | 4.40B | 4.62B | 4.35B | 3.99B | 2.99B | 2.89B | 2.96B | 3.40B | 2.71B | 2.70B | 2.54B | 2.38B | 1.86B | 1.82B | 1.67B | 2.13B | 2.24B |
| Other Expenses | 1.08B | 1.03B | 777.00M | 841.00M | 767.00M | 521.00M | 681.00M | 431.00M | 342.80M | 65.80M | 62.70M | 70.80M | 68.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.83B | 8.95B | 8.14B | 7.89B | 7.84B | 7.58B | 7.63B | 7.53B | 6.60B | 5.68B | 5.38B | 5.55B | 6.50B | 5.80B | 5.07B | 4.52B | 4.30B | 2.74B | 2.62B | 2.05B | 3.05B | 3.11B |
| Cost & Expenses | 17.38B | 17.48B | 15.49B | 14.72B | 13.85B | 12.97B | 12.95B | 12.73B | 10.68B | 9.74B | 8.94B | 9.28B | 9.29B | 8.19B | 7.10B | 6.43B | 6.08B | 5.15B | 4.99B | 4.30B | 6.62B | 6.90B |
| Interest Income | 121.00M | 71.00M | 46.00M | 39.00M | 66.00M | 55.00M | 26.00M | 20.00M | 32.00M | 30.60M | 30.10M | 35.60M | 57.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 272.00M | 235.00M | 272.00M | 387.00M | 476.00M | 339.00M | 348.00M | 342.00M | 348.80M | 222.70M | 248.00M | 301.20M | 319.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.88B | 1.80B | 1.71B | 1.76B | 1.91B | 1.75B | 1.76B | 1.81B | 1.51B | 1.36B | 1.46B | 1.40B | 1.60B | 1.26B | 1.00B | 1.22B | 923.60M | 303.00M | 289.50M | 375.00M | 470.50M | 425.20M |
| EBITDA | 5.69B | 6.55B | 5.96B | 4.73B | 4.16B | 3.60B | 4.25B | 4.43B | 3.35B | 3.14B | 3.10B | 2.41B | 2.76B | 2.36B | 1.65B | 2.35B | 1.90B | 1.10B | 1.17B | 1.42B | 1.01B | 920.00M |
| EBITDA Ratio | 27.08% | 30.33% | 30.28% | 26.97% | 26.18% | 25.00% | 27.29% | 27.90% | 28.19% | 27.73% | 33.03% | 29.29% | 23.65% | 25.45% | 21.65% | 36.34% | 37.90% | 19.00% | 18.72% | 26.57% | 17.32% | 13.20% |
| Operating Income | 3.61B | 4.47B | 4.18B | 2.99B | 2.12B | 1.73B | 2.53B | 2.48B | 1.84B | 1.76B | 1.61B | 963.60M | 985.10M | 1.11B | 620.90M | 731.40M | 975.70M | 1.11B | 955.60M | 1.04B | 579.30M | 494.80M |
| Operating Income Ratio | 17.19% | 20.12% | 21.23% | 17.02% | 13.13% | 11.64% | 16.47% | 16.51% | 14.35% | 15.32% | 14.52% | 8.62% | 9.59% | 11.94% | 8.01% | 9.68% | 13.83% | 17.67% | 16.28% | 19.54% | 8.04% | 6.69% |
| Total Other Income/Expenses | -125.00M | -187.00M | -255.00M | -355.00M | -385.00M | -266.00M | -294.00M | -327.00M | -356.00M | -205.00M | -222.20M | -1.13B | -293.30M | -248.30M | -159.00M | -156.50M | -1.09B | 167.90M | 11.90M | -82.70M | -156.70M | -83.20M |
| Income Before Tax | 3.48B | 4.29B | 3.92B | 2.63B | 1.74B | 1.46B | 2.22B | 2.15B | 1.49B | 1.56B | 1.39B | 709.00M | 851.10M | 861.10M | 486.40M | 574.90M | -110.90M | 1.27B | 893.40M | 960.80M | 422.60M | 411.60M |
| Income Before Tax Ratio | 16.60% | 19.28% | 19.93% | 15.00% | 10.74% | 9.85% | 14.51% | 14.34% | 11.57% | 13.54% | 12.52% | 6.35% | 8.28% | 9.27% | 6.28% | 7.61% | -1.57% | 20.35% | 15.22% | 17.99% | 5.87% | 5.56% |
| Income Tax Expense | 650.00M | 948.00M | 859.00M | 637.00M | 440.00M | 368.00M | -386.00M | 521.00M | 368.00M | 392.20M | 179.50M | 130.00M | 222.10M | 219.60M | 109.70M | 195.80M | -23.10M | 272.20M | 220.70M | 288.90M | 204.90M | 196.40M |
| Net Income | 2.82B | 3.33B | 3.06B | 1.99B | 1.32B | 3.37B | 2.61B | 1.63B | 1.12B | 1.16B | 1.20B | 566.70M | 606.50M | 641.50M | 376.70M | 379.10M | 3.52B | 1.00B | 672.70M | 671.90M | 217.70M | 215.20M |
| Net Income Ratio | 13.45% | 14.96% | 15.52% | 11.33% | 8.17% | 22.74% | 17.00% | 10.84% | 8.68% | 10.06% | 10.84% | 5.07% | 5.90% | 6.90% | 4.86% | 5.02% | 49.88% | 16.00% | 11.46% | 12.58% | 3.02% | 2.91% |
| EPS | 6.49 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| EPS Diluted | 6.50 | 7.65 | 7.03 | 4.57 | 3.04 | 7.76 | 5.99 | 3.75 | 2.56 | 2.66 | 2.77 | 1.31 | 1.40 | 1.46 | 0.84 | 0.85 | 8.11 | 2.54 | 1.67 | 1.71 | 0.57 | 0.58 |
| Weighted Avg Shares Out | 435.13M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.40M | 434.78M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
| Weighted Avg Shares Out (Dil) | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 434.89M | 434.40M | 435.55M | 435.08M | 434.01M | 434.25M | 434.77M | 434.80M | 434.80M | 434.80M | 431.80M | 388.00M | 393.65M | 385.12M | 366.84M | 349.37M |
Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced new research from the company's diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, Chicago. Data...
Merck KGaA (MKGAF) Q1 2024 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q1 2024 Results Conference Call May 15, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Matthias Heinzel - CEO, Life Science...
Merck KGaA's Q1 adjusted profit declines less than feared
Merck KGaA on Wednesday reported better-than-expected adjusted earnings, helped by strong demand for its pharmaceuticals and amid currency-adjusted sales growth in semiconductor materials.
Merck KGaA (MKGAF) Q4 2023 Earnings Call Transcript
Merck KGaA (OTCPK:MKGAF) Q4 2023 Results Conference Call March 7, 2024 8:00 AM ET Company Participants Constantin Fest - Head of Investor Relations Belen Garijo - Chair & CEO Helene von Roeder - CFO Matthias Heinzel - CEO, Life Science...
Merck KGaA forecasts return to organic earnings growth in 2024
Merck KGaA predicted a return to modest operating earnings growth, when adjusted for currency headwinds, citing a gradual recovery in demand for specialty materials that are used to make biotech drugs and semiconductors.
4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.
Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.
Merck KGaA's experimental MS drug fails in late stage trials sending shares tumbling
Merck KGaA shares plunged more than 12% on Wednesday after the company announced that its experimental multiple sclerosis (MS) drug evobrutinib failed to meet the primary endpoint in Phase 3 clinical trials. The company said that its drug did not...
Merck KGaA says MS drug fails in late-stage trials
Germany's Merck KGaA said on Tuesday the company's experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.
Evotec: Attractive Spec 'Buy', But Merck KGaA Is Still Better
Evotec SE's appeal is based on its valuation and upside potential in the drug discovery and development sector. The company's financial performance is average, with negative margins and subpar business model specifics for 2022. Despite some issues, EVO remains a...
Merck KGaA Q3 earnings down 20% on weak biotech, electronics demand
Germany's diversified group Merck KGaA reported a 20% decline in quarterly operating profit on weak demand for specialty materials that are used to make biotech drugs and semiconductors.
Source: https://incomestatements.info
Category: Stock Reports